Rosetta Genomics Ltd. ("Rosetta") (NASDAQ: ROSG) today announced the pricing of an underwritten public offering of 5,500,000 ordinary shares at a public offering price of $5.00 per share. The gross proceeds to Rosetta from this offering are expected to be approximately $27.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by Rosetta. The offering is expected to close on or about August 8, 2012, subject to the satisfaction of customary closing conditions. In addition, Rosetta has granted the underwriter a 45-day option to purchase up to 825,000 additional ordinary shares to cover over-allotments, if any.(c) 2012 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Reserve your seat now for MedCity CONVERGE, to be held July 9-10 in Philadelphia. Discover strategies, solutions and startups in healthcare innovation. Be a part of this gathering where the entire healthcare ecosystem converges.